Emerging therapeutics in the management of connective tissue disease. Part II: Dermatomyositis and scleroderma

The management of connective tissue diseases is dramatically evolving with the advent of biologics and novel oral systemic therapeutics. Despite involvement in the care of these complex patients, there is a knowledge gap in the field of dermatology regarding these emerging agents. The second article...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Academy of Dermatology 2022-07, Vol.87 (1), p.21-38
Main Authors: Kodumudi, Vijay, Bibb, Lorin A., Adalsteinsson, Jonas A., Shahriari, Neda, Skudalski, Lauren, Santiago, Sueheidi, Grant-Kels, Jane M., Lu, Jun
Format: Article
Language:English
Subjects:
clinical trials
clinically amyopathic dermatomyositis
current management dermatomyositis
juvenile dermatomyositis
scleroderma
systemic sclerosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The management of connective tissue diseases is dramatically evolving with the advent of biologics and novel oral systemic therapeutics. Despite involvement in the care of these complex patients, there is a knowledge gap in the field of dermatology regarding these emerging agents. The second article in this continuing medical education series discusses new and emerging therapeutics for dermatomyositis and scleroderma that target cells, intracellular signaling pathways, and cytokines.
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2021.12.068